Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$26.97

0.54 (2.04%)

12:32
10/11/19
10/11
12:32
10/11/19
12:32

Horizon says new data from teprotumumab study shows 'significant benefit'

Horizon Therapeutics announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease, or TED, compared with placebo, including diplopia, quality of life and clinical activity score. These data were presented during the American Society of Ophthalmic Plastic and Reconstructive Surgery 50th Anniversary 2019 Fall Scientific Symposium, and build upon data presented earlier this year that demonstrated the significant benefit of teprotumumab on proptosis. Teprotumumab is an investigational medicine for the treatment of active TED and is currently under review by the FDA. The teprotumumab Biologics License Application, or BLA, was recently granted Priority Review by the FDA and if approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED. The Prescription Drug User Fee Act, or PDUFA, goal date is March 8, 2020.

  • 11

    Oct

  • 06

    Nov

HZNP Horizon Pharma
$26.97

0.54 (2.04%)

08/26/19
PIPR
08/26/19
NO CHANGE
Target $33
PIPR
Overweight
Horizon Pharma risk/reward 'highly attractive,' says Piper Jaffray
After conducting a survey of 27 physicians who manage significant numbers of patients with thyroid eye disease, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $33 price target. The analyst says the survey reinforced his belief that teprotumumab will over time emerge as a go-to option in a broad swath of moderate-to-severe TED patients. He continues to view Horizon as one of the most attractive longer-term EBITDA growth stories in the broader biopharma space. Amsellem sees a "highly attractive" risk/reward profile at current share levels.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Horizon Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Horizon Pharma with a Buy rating and a $36 price target, calling the company his "Best Idea." The analyst has high confidence in the growth potential of Horizon's drugs Krystexxa and teprotumumab, and believes they will drive upside to margins over the next 3-5 years. Flanders also expects a "strong" tepro launch in Q1 of 2020.
09/26/19
BOFA
09/26/19
INITIATION
Target $34
BOFA
Buy
Horizon Pharma initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Horizon Pharma with a Buy rating and a price target of $34. The analyst contends that the stock can generate multiple expansion from its tepro approval and favorable payer coverage for thyroid eye disease as well as from the continued execution of Krystexxa re-launch and the "read-across to tepro launch hurdles".
10/11/19
PIPR
10/11/19
NO CHANGE
Target $33
PIPR
Overweight
Piper Jaffray rheumatologist survey favorable for Horizon Pharma
Piper Jaffray analyst David Amsellem says his survey of 25 rheumatologists who are current users of Horizon Pharma's Krystexxa in patients with chronic refractory gout reinforced his view that the rheumatology community's view of the risk/benefit profile of the product "continues to evolve considerably, pointing to greater usage among existing Krystexxa users." The feedback also bodes well for usage of the product among practices that are relatively new to Krystexxa, Amsellem tells investors in a research note. He continues to believe that the combination of "continued aggressive" Krystexxa growth along with contribution from teprotumumab starting next year points to a longer term annual EBITDA growth for Horizon "at least in the high-teens." Amsellem keeps an Overweight rating on the shares with a $33 price target.

TODAY'S FREE FLY STORIES

02:55
11/12/19
11/12
02:55
11/12/19
02:55
General news
FX Update: The yen took a rotation lower »

FX Update: The yen took a…

01:50
11/12/19
11/12
01:50
11/12/19
01:50
General news
Asian Market Update »

Asian Market Update:…

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:44
11/11/19
11/11
20:44
11/11/19
20:44
Earnings
Nesco Holdings cuts FY19 revenue view to $255M-$262M from $278M »

One estimate $279.6M. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:42
11/11/19
11/11
20:42
11/11/19
20:42
Earnings
Nesco Holdings reports Q3 EPS (45c), one estimate 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FTK

Flotek

$1.86

-0.1 (-5.10%)

20:29
11/11/19
11/11
20:29
11/11/19
20:29
Earnings
Flotek reports Q3 EPS (19c), one estimate (23c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RF

Regions Financial

$16.77

-0.1 (-0.59%)

20:27
11/11/19
11/11
20:27
11/11/19
20:27
Downgrade
Regions Financial rating change at BMO Capital »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

TSN

Tyson Foods

$82.70

0.12 (0.15%)

, ROK

Rockwell Automation

$180.00

2.25 (1.27%)

20:25
11/11/19
11/11
20:25
11/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TSN

Tyson Foods

$82.70

0.12 (0.15%)

ROK

Rockwell Automation

$180.00

2.25 (1.27%)

DHI

D.R. Horton

$52.65

1.535 (3.00%)

CBS

CBS

$39.21

1.09 (2.86%)

AAP

Advance Auto Parts

$168.41

1.17 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

RMTI

Rockwell Medical

$1.92

0.07 (3.78%)

20:01
11/11/19
11/11
20:01
11/11/19
20:01
Recommendations
Rockwell Medical analyst commentary at Piper Jaffray »

Rockwell Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APYX

Apyx Medical

$7.22

0.24 (3.44%)

19:39
11/11/19
11/11
19:39
11/11/19
19:39
Recommendations
Apyx Medical analyst commentary at Piper Jaffray »

Apyx Medical price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

FOE

Ferro

$12.58

0.07 (0.56%)

, APYX

Apyx Medical

$7.22

0.24 (3.44%)

18:59
11/11/19
11/11
18:59
11/11/19
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ferro…

FOE

Ferro

$12.58

0.07 (0.56%)

APYX

Apyx Medical

$7.22

0.24 (3.44%)

KEM

Kemet

$23.03

-0.51 (-2.17%)

ICUI

ICU Medical

$168.41

1.43 (0.86%)

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

GO

Grocery Outlet

$31.09

-0.06 (-0.19%)

CMLS

Cumulus Media

$13.59

0.07 (0.52%)

FGEN

FibroGen

$35.37

-6.24 (-15.00%)

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

LYV

Live Nation

$64.47

1.31 (2.07%)

FLNT

Fluent

$2.54

0.11 (4.53%)

ASUR

Asure Software

$9.20

0.01 (0.11%)

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

FPI

Farmland Partners

$6.66

-0.125 (-1.84%)

RETA

Reata Pharmaceuticals

$213.52

1.48 (0.70%)

JCOM

j2 Global

$100.62

0.23 (0.23%)

PCG

PG&E

$6.24

-0.23 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 07

    Jan

CRL

Charles River

$131.58

1.19 (0.91%)

18:57
11/11/19
11/11
18:57
11/11/19
18:57
Hot Stocks
Charles River CEO: We are pleased with the demand curve »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.24

-0.23 (-3.55%)

18:44
11/11/19
11/11
18:44
11/11/19
18:44
Periodicals
PG&E offers $13.5B in compensation to victims of CA fires, Bloomberg says »

PG&E is offering to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:27
11/11/19
11/11
18:27
11/11/19
18:27
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Kemet up 14.7% to $26.40…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NCLH

Norwegian Cruise Line

$51.90

0.07 (0.14%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Hot Stocks
Norwegian Cruise Line CEO: North American consumer is alive and well »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$12.58

0.07 (0.56%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Earnings
Ferro reports Q3 adjusted EPS 35c, consensus 28c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:09
11/11/19
11/11
18:09
11/11/19
18:09
Hot Stocks
Yageo to acquire Kemet for $27.20 per share in cash, or $1.8B »

Yageo and Kemet announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PAR

Par Technology

$30.23

1.07 (3.67%)

18:08
11/11/19
11/11
18:08
11/11/19
18:08
Recommendations
Par Technology analyst commentary at Jefferies »

Par Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:06
11/11/19
11/11
18:06
11/11/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Yageo to acquire Kemet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CSX

CSX

$73.93

-0.08 (-0.11%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Downgrade
CSX rating change at Deutsche Bank »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TDW

Tidewater

$17.14

-0.34 (-1.95%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Earnings
Tidewater reports Q3 adjusted EPS (99c), may not compare to consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UNVR

Univar

$23.87

-0.08 (-0.33%)

17:57
11/11/19
11/11
17:57
11/11/19
17:57
Hot Stocks
Univar named EMEA distributor for Kaopolite Abrasive in Europe »

Univar B.V., a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$46.48

0.44 (0.96%)

17:56
11/11/19
11/11
17:56
11/11/19
17:56
Hot Stocks
NexPoint Residential acquires three-property portfolio in Las Vegas for $241M »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.